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on a wide range. The increase of the mother’s educational level is in signiﬁ cantly posi-
tive relationship with the DS person’s computing (khi2 = 14,314, p = 0,026), drawing/
writing (khi2 = 21,027, p = 0,002) and reading (khi2 = 22,169, p = 0.001) perfor-
mance. It has a favourable effect on the development of the basic self-supporting skills 
(khi2 = 25,571, P < 0.001), and the DS person’s social connections. The majority of 
those lacking friends live with mothers with the lowest qualiﬁ cation (khi2 = 9.799, p 
= 0.02). The level of happiness was measured on a four-grade scale. Owing to a mental 
retardation of medium gravity, surveying was carried out in an indirect way, by 
questioning the parents. The higher parental qualiﬁ cations associated with happier DS 
people (khi2 = 17,344, p = 0.008). The parents’ educational levels are correlated (r = 
0.609, P < 0.001). CONCLUSIONS: More qualiﬁ ed parents provide supportive envi-
ronment rich in stimuli. Higher level of development reduces the DS person’s depen-
dence on others, increases their self-estimation, the level of happiness and through this 
the quality of life improves. It means a smaller burden on the health care system, the 
society and the family. However the professionals taking part in family support must 
be reminded that not every family can perform special child educational tasks inde-
pendently, and they need more intensive family support. 
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OBJECTIVES: Behavioural and psychological symptoms of dementia such as aggres-
siveness, agitation and psychosis are common and very distressful for Alzheimer’s 
disease patients and their caregivers. Their occurrence leads to an increased use of 
psychotropic medications. Memantine treatment has demonstrated signiﬁ cant beneﬁ t 
on these symptoms in the experimental setting of randomized clinical trials. The 
objective of this study was to assess the impact of memantine treatment initiation on 
the use of psychotropic medications in real life practice. METHODS: A retrospective 
prescription claims analysis was conducted using the Quebec provincial public health 
plan (RAMQ) database. Data on medical and pharmaceutical services were obtained 
for the period from January 2004 to March 2009 for a random sample of patients 
who received at least one scripts of memantine. Trends in the proportion of patients 
using psychotropic drugs, antidepressants, neuroleptics, and anti-anxiety agents were 
estimated one year before and after the ﬁ rst prescription of memantine. RESULTS: 
Data were obtained from the RAMQ for a total of 2,007 patients. The study sample 
was 82.2 years old on average (SD = 7.6), with 67.6% of female. Proportion of 
patients using a psychotropic drug in the year preceding the initiation of memantine 
increased by 58.5%, from a proportion of 0.450 to 0.713 while this proportion only 
increased by 3.5% (0.713 to 0.738) in the year following the memantine initiation. 
The increase in proportion of users of antidepressants, neuroleptics, and anti-anxiety 
agents before and after initiation of memantine were 48.3% (0.239 to 0.354) vs. 2.8% 
(0.354 to 0.364), 112.1% (0.219 to 0.465) vs. 1.9% (0.465 to 0.474) and 41.3% 
(0.175 to 0.247) vs. 1.5% (0.247 to 0.250) respectively. CONCLUSIONS: Results of 
this prescription claims analysis indicate that the increasing rate of psychotropic drugs, 
antidepressants, neuroleptics, and anti-anxiety agents use signiﬁ cantly decrease after 
the initiation of memantine.
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OBJECTIVES: Existing assessments of the health related quality of life (HRQoL) in 
patients with multiple sclerosis have focused on persons with the disease. What has 
not been assessed is the extent to which the presence of multiple sclerosis generates 
HRQoL deﬁ cits compared to the general population. METHODS: Data are from the 
internet-based 2008 National Health and Wellness Survey in the UK, France, Spain, 
Italy and Germany. a total of 53,524 respondents completed the survey form, of whom 
308 indicated they had a diagnosis of multiple sclerosis. Respondents completed the 
SF-12 generic HRQoL instrument. The analysis is based on the summary mental 
component scores (MCS), physical component scores (PCS) and health state utilities 
from the SF-6D items derived from the SF-12 instrument. a multivariate analysis (using 
ordinary least squares) was undertaken with the MCS, PCS and SF-6D utilities as 
dependent variables. The independent variables included a binary variable for the 
presence/absence of multiple sclerosis, socio-demographic characteristics, health risk 
factors (e.g., body mass index), country dummy variables and the Charlson Comorbid-
ity Index (CCI). RESULTS: Persons reporting multiple sclerosis had substantially 
lower PCS scores (32.19 vs. 48.66; t = 24.60); MCS scores (39.78 vs. 46.53; t = 10.18) 
and utility scores (0.57 vs. 0.72; t = 23.57). In the multivariate modeling, the deﬁ cit 
associated with the presence of multiple sclerosis was substantially greater than any 
other independent variable in the PCS (−12.07; 95% CI: −14.02 to −10.12) and utility 
models (−0.11; 95% CI: −0.13 to −0.09). The utility decrement in the SF-6D model 
attributed to multiple sclerosis far outweighed the utility deﬁ cits attributable to the 
other independent variables. CONCLUSIONS: Compared to the non-multiple sclero-
sis population, there are substantial HRQoL deﬁ cits associated with the diagnosis of 
multiple sclerosis. These deﬁ cits are substantial and far outweigh those attributable 
to socio-demographic characteristics, health risk factors and the presence of 
comorbidities.
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OBJECTIVES: Management of drug-resistant epileptic patients includes different sur-
gical alternatives. The target patient (i.e. resistant to at least 2 anti-epileptic drugs) 
may undergo neurosurgery or Vagal Nerve Stimulation (VNS). Scope of this work 
was to estimate hospital costs for neurosurgery and VNS and compare with Regional 
funding. METHODS: Investigated phases were: Non-Invasive Diagnostics-NID, 
Invasive-ID, Neurosurgery Intervention-NI or VNS-I, FollowUP-FUP, in 6 referral 
centres. Average/patient cost was estimated by microcosting; resource consumption 
by questionnaire; unit costs valued by full hospital costs (staff, operating-room, hos-
pital-stay), outpatient-tariffs (diagnostics), market-prices (drugs, devices) at 2010 
values. RESULTS: NID-phase: c5070/adult (c3516-c7356) and c4382/child. Ranges 
reﬂ ect variability of hospital-stay and staff time; 79% of total cost is due to diagnos-
tics. DI-phase costs c15,900/adult (37%) and c16,261/child (44%). The cost range 
for adults (c14,098-c17,702) reﬂ ects variability of invasive video-EEG protocols. 
Regional funding is under-remunerative. Considering individual procedures, video-
EEG costs c3,406/adult (cost driver: staff workload); invasive-video-EEG c34,790 
(driver: electrodes). For children, video-EEG costs c3,063 and invasive-video-EEG 
c27,619; lower values are due to higher seizures frequency and shorter duration of 
recordings. Neurosurgery intervention cost is c16,230/adult and c18,894/child. For 
adults, variability (c14,730-c18,513) depends on the duration of intervention, number 
and cost of staffs. Intervention cost is similar in the three Regions and hospital imbal-
ance is the result of under-funding by regional tariffs. VNS insertion cost is c24,543/
adult (c3,518 for the intervention). Under-remuneration by tariffs is conﬁ rmed, even 
considering regional extra-tariffs for the device. Global treatment path for an adult 
(NID + intervention + FUP 5°yrs) amounts to c23,571-NI and c33,373-VNSI; for a 
child c20,066-NI. Regional data: Lombardy, c23,571-NI and c32,244-VNSI, for 
Lazio c25,571-NI and c34,176-VNSI, for Emilia Romagna c22,886-NI and c34,871-
VNSI. CONCLUSIONS: Funding of the management of resistant epilepsies in the 
target patient appears insufﬁ cient to cover costs actually incurred by Italian hospitals, 
irrespective of organization and Regional funding. 
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BACKGROUND: Currently, data-access barriers exist throughout key European 
health-technology assessment countries, including Sweden. Patient registries are of 
limited use due to frequent lapses in data integrity, completeness and limitations 
around access to these data. Additionally, data-protection legislation often prohibits 
the use of existing data from providers and insurance funds. These limitations hinder 
the development of longitudinal health-technology assessments required to evaluate 
the cost-effectiveness of new and existing therapeutics. OBJECTIVES: To explore the 
opportunities and limitations of applying non-local, longitudinal, patient-level treat-
ment and outcomes data to the Swedish environment. METHODS: A large, longitu-
dinal, patient-level treatment and outcomes data set (>55 million US patients from 
>90 health insurance plans) from the USA was used to create a sample of patients 
with multiple sclerosis who were undergoing treatment with disease-modifying drugs. 
Patient outcomes were evaluated with regard to the extent to which patients were 
adherent to therapy. Based on adherence levels, patient tendency to use incremental 
health care system resources was assessed. Adaptation to the local Swedish environ-
ment was performed by incorporating or acknowledging customary aspects of the 
Dental and Pharmaceutical Beneﬁ ts Board (Tandvårds-och läkemedelsförmånsverket) 
cost-beneﬁ t analysis. Costs of outcomes, speciﬁ cally interventions as a result of non-
adherence, were based on Swedish cost-estimates from prior independent research. 
CONCLUSIONS: When performing a cost-effectiveness analysis, incorporation of 
patient-level data from another country invokes caveats on the results, including dif-
ferences in access to care, cultural attitudes and social beliefs. However, in the absence 
of accessible local data, complete and sufﬁ cient data from another country (e.g., the 
USA) can serve as a surrogate. This may limit the broad acceptance of the study’s 
results; however, it provides quantitatively supported and customized results based 
upon a robust data set, upon which health care decision-makers can derive resource 
allocation and prescribing decisions.
